Phospho-RASGRF1 (S916) Antibody

What is RASGRF1 and what is the significance of its phosphorylation at Serine 916?

RASGRF1 (RAS protein-specific guanine nucleotide-releasing factor 1) is a guanine nucleotide exchange factor (GEF) that facilitates the activation of Ras proteins by catalyzing the exchange of GDP for GTP. This 145 kDa protein plays a critical role in signal transduction pathways following stimulation of cell surface receptors.

Phosphorylation at Serine 916 represents a specific post-translational modification that regulates RASGRF1 activity. Research indicates that RASGRF1 becomes phosphorylated at S916 in response to several stimuli, including:

• Pro-metastatic factors (SDF-1, HGF/SF)

• Growth-promoting factors (IGF-2, insulin)

• Calcium signaling pathways

This phosphorylation event is associated with subsequent activation of downstream signaling pathways, particularly p42/44 MAPK and AKT pathways, which influence cell proliferation, differentiation, and survival .

What are the primary research applications for Phospho-RASGRF1 (S916) antibodies?

Phospho-RASGRF1 (S916) antibodies have been validated for multiple research applications:

These antibodies specifically detect endogenous levels of RASGRF1 protein only when phosphorylated at Serine 916, making them valuable tools for monitoring this specific post-translational modification .

What are the species reactivity profiles of available Phospho-RASGRF1 (S916) antibodies?

The commercially available Phospho-RASGRF1 (S916) antibodies show different species reactivity profiles:

It's important to note that species reactivity can vary between lots and should be verified for your specific experimental system .

How should samples be prepared for optimal detection of phosphorylated RASGRF1?

Optimal sample preparation is critical for preserving the phosphorylation status of RASGRF1 at S916:

• Cell/Tissue Lysis:

  • Use ice-cold lysis buffer containing phosphatase inhibitors

  • For cell lines, quiescent cells (0.5% BSA medium) should be stimulated with appropriate factors (SDF-1, HGF/SF, IGF-2, insulin) for 5 minutes at 37°C before lysis

  • Process samples quickly to prevent dephosphorylation

• Protein Preservation:

  • Include both protease and phosphatase inhibitors in all buffers

  • Common phosphatase inhibitors: sodium fluoride, sodium orthovanadate, β-glycerophosphate, and sodium pyrophosphate

  • Maintain cold temperature throughout processing

• Storage Conditions:

  • For antibodies: Store at -20°C for long-term storage; avoid repeated freeze-thaw cycles

  • For protein extracts: Aliquot and store at -80°C; use fresh samples when possible

• Fixation for Microscopy:

  • For immunohistochemistry: 10% buffered formalin fixation is compatible

  • For cell immunofluorescence: 4% paraformaldehyde followed by careful permeabilization

What are the most effective validation methods to ensure specificity of Phospho-RASGRF1 (S916) antibody results?

Multiple complementary approaches should be used to validate the specificity of Phospho-RASGRF1 (S916) antibody signals:

• Phosphopeptide Competition Assays:

  • Pre-incubate antibody with phosphorylated peptide (containing S916)

  • Pre-incubate with non-phosphorylated equivalent peptide

  • Only the phosphorylated peptide should abolish specific signal

• Phosphatase Treatment Controls:

  • Treat duplicate samples with lambda phosphatase

  • Signal should be eliminated or significantly reduced after phosphatase treatment

• Stimulation/Inhibition Paradigms:

  • Compare unstimulated cells with cells stimulated by factors known to induce S916 phosphorylation

  • Include inhibitors of upstream kinases to demonstrate pathway specificity

  • For example, stimulation with SDF-1, HGF/SF, IGF-2, or insulin should increase signal

• Genetic Controls:

  • Use RasGRF1 knockdown or knockout models

  • Signal should be absent or significantly reduced in these samples

• Multiple Detection Methods:

  • Confirm findings using different techniques (WB, IHC, IF)

  • Results should be consistent across methodologies

What are the recommended positive control samples for Phospho-RASGRF1 (S916) antibody experiments?

Based on the literature and available resources, these samples provide reliable positive controls:

For stimulation experiments, treatment with SDF-1 (300 ng/ml), HGF/SF (100 ng/ml), IGF-II (100 ng/ml), or insulin (10 ng/ml) for 5 minutes has been shown to induce RASGRF1 phosphorylation at S916 .

How does phosphorylation at S916 affect the function of RASGRF1 in different cellular contexts?

The functional consequences of S916 phosphorylation appear to be context-dependent:

• Cancer Progression:

  • In alveolar rhabdomyosarcoma (ARMS), S916 phosphorylation correlates with activation of p42/44 MAPK and AKT pathways

  • Knockdown of RasGRF1 inhibits cell proliferation and tumor formation in vivo

  • Phosphorylation occurs in response to metastasis-promoting factors (SDF-1, HGF/SF)

• Neuronal Function:

  • In neuronal cells, RASGRF1 phosphorylation modulates synaptic plasticity

  • Chronic cerebral hypoperfusion leads to decreased RASGRF1 levels and cognitive dysfunction

  • Upregulation of RASGRF1 ameliorates spatial cognitive dysfunction

• Signal Integration:

  • The IQ motif, coiled-coil, and PH domains appear to function as a unit in localizing GRF1 to cell membranes

  • This localization enables RASGRF1 to respond to calcium signals

  • Phosphorylation at S916 may affect this localization and subsequent signaling capacity

• Isoform-Specific Effects:

  • Different splicing isoforms of RASGRF1 may be differently affected by S916 phosphorylation

  • The full-length p140-GRF1 contains all regulatory domains

  • Smaller isoforms like p55-GRF1 lack certain domains (e.g., IQ motif) and likely respond differently to regulatory signals

What signaling pathways regulate RASGRF1 phosphorylation at S916, and how can these be experimentally manipulated?

Multiple signaling pathways converge on RASGRF1 phosphorylation at S916:

• Calcium-Dependent Pathways:

  • Calcium influx activates calmodulin, which interacts with the IQ domain of RASGRF1

  • This interaction can be experimentally manipulated using:

    • Calcium ionophores (e.g., A23187)

    • Calcium chelators (e.g., BAPTA-AM)

    • Calmodulin antagonists (e.g., W-7)

• G-Protein Coupled Receptor (GPCR) Signaling:

  • GPCRs like CXCR4 (SDF-1 receptor) can trigger RASGRF1 phosphorylation

  • Experimental approaches include:

    • Receptor-specific agonists (SDF-1/CXCL12)

    • Receptor antagonists (AMD3100 for CXCR4)

    • G-protein inhibitors (pertussis toxin for Gi)

• Receptor Tyrosine Kinase (RTK) Signaling:

  • Growth factor receptors (IGF-1R, EGFR) activate RASGRF1

  • Manipulate with:

    • Growth factors (IGF-2, insulin)

    • Receptor-specific inhibitors (e.g., tyrphostins)

    • Downstream kinase inhibitors

• Kinases Responsible for S916 Phosphorylation:

  • While the specific kinase(s) that phosphorylate S916 haven't been definitively identified, candidates include:

    • PKA (inhibit with H-89)

    • PKC (inhibit with GF109203X)

    • p38 MAPK (inhibit with SB203580)

    • Experimental approaches should include kinase inhibitor panels to identify the responsible enzyme(s)

How can phospho-RASGRF1 (S916) antibodies be effectively utilized in analyzing disease models and potential therapeutic interventions?

Phospho-RASGRF1 (S916) antibodies can provide valuable insights in various disease contexts:

• Cancer Research:

  • Monitor RASGRF1 activation status in tumor samples

  • Track pharmacodynamic responses to targeted therapies

  • Potential applications:

    • Tissue microarrays for prognostic assessment

    • Patient-derived xenograft response monitoring

    • Correlation with drug resistance mechanisms

• Neurological Disorders:

  • Assess RASGRF1 phosphorylation in models of:

    • Chronic cerebral hypoperfusion

    • Neurodegenerative diseases

    • Learning and memory disorders

  • Experimental approaches:

    • Behavioral tests correlated with biochemical analysis

    • Ex vivo slice preparations for electrophysiology and immunostaining

    • In vivo imaging of phosphorylation status

• Therapeutic Target Validation:

  • RasGRF1 knockdown reduces tumor growth in ARMS models

  • Phosphorylation status can serve as a biomarker for:

    • Target engagement

    • Downstream pathway activation

    • Resistance mechanisms

• Methodological Considerations for Disease Models:

  • Combine multiple techniques:

    • Western blot for quantification

    • IHC for spatial distribution in tissues

    • IF for subcellular localization

  • Include time-course analyses to capture dynamic changes

  • Correlate phosphorylation with functional outcomes relevant to the disease model

What are common challenges in detecting phosphorylated RASGRF1 and how can they be addressed?

Several technical challenges can affect detection of phosphorylated RASGRF1 at S916:

• High Molecular Weight:

  • RASGRF1 is a large protein (~145 kDa) that can be difficult to transfer efficiently

  • Solution: Use extended transfer times or lower percentage gels (6-8%); consider wet transfer systems for larger proteins

• Phospho-Epitope Lability:

  • Phosphorylation can be lost during sample processing

  • Solution: Always include phosphatase inhibitors in lysis buffers; process samples quickly and maintain cold temperatures; avoid repeated freeze-thaw cycles

• Antibody Cross-Reactivity:

  • Some phospho-specific antibodies may recognize similar phospho-epitopes

  • Solution: Include appropriate controls (phosphopeptide competition, RasGRF1 knockdown samples); verify with multiple antibodies if possible

• Fixation-Induced Epitope Masking:

  • Formalin fixation can mask epitopes in IHC applications

  • Solution: Optimize antigen retrieval methods (heat-induced epitope retrieval in citrate buffer at pH 6.0 has been validated)

• Signal-to-Noise Ratio:

  • Background staining can obscure specific signals

  • Solution: Optimize blocking conditions; use phospho-specific blocking reagents; increase washing steps; titrate antibody concentration

How can researchers interpret conflicting results between different detection methods for phosphorylated RASGRF1?

When faced with discrepancies between different detection methods:

How can phospho-RASGRF1 (S916) antibodies be incorporated into multiplexed detection systems for comprehensive pathway analysis?

Multiplexed detection offers a more comprehensive view of RASGRF1 signaling networks:

• Multiplex Immunofluorescence Approaches:

  • Combine phospho-RASGRF1 (S916) antibody with antibodies against:

    • Total RASGRF1 (to calculate phosphorylation ratio)

    • Upstream activators (e.g., receptor status)

    • Downstream effectors (phospho-ERK1/2, phospho-AKT)

  • Technical considerations:

    • Use antibodies from different host species

    • Employ sequential staining if using same-species antibodies

    • Carefully validate spectral separation of fluorophores

• Multiplex Western Blotting:

  • Sequential Probing:

    • Strip and reprobe membranes for different targets

    • Begin with phospho-specific antibodies before stripping

  • Same-Blot Multiplexing:

    • Use antibodies with distinct molecular weight targets

    • Employ different host species with spectrally distinct secondary antibodies

• Phospho-Protein Array Technologies:

  • Custom arrays can include phospho-RASGRF1 (S916) alongside other pathway components

  • Offers higher throughput than traditional Western blotting

  • Requires careful validation of antibody specificity in the array format

• Single-Cell Analysis Techniques:

  • Flow cytometry for phospho-protein detection

    • Requires optimization of fixation and permeabilization

    • Enables correlation with other cellular markers

  • Mass cytometry (CyTOF) for higher-dimensional analysis

    • Metal-conjugated antibodies allow for 40+ parameters

    • Can correlate RASGRF1 phosphorylation with numerous pathway components at single-cell resolution

• Spatial Analysis Systems:

  • Digital spatial profiling technologies

  • Multiplexed ion beam imaging (MIBI)

  • These approaches maintain spatial information while enabling multiplexed detection of phosphorylation events

Each of these approaches requires careful optimization and validation of antibody specificity in the specific experimental context.

What role might RASGRF1 phosphorylation at S916 play in neurological disorders and potential therapeutic development?

Emerging research suggests significant implications for RASGRF1 phosphorylation in neurological function and disorders:

• Cognitive Function and Dysfunction:

  • RASGRF1 levels decrease following chronic cerebral hypoperfusion (CCH)

  • Upregulation of RASGRF1 ameliorates spatial cognitive dysfunction

  • S916 phosphorylation may be a critical regulatory mechanism in these processes

• Synaptic Plasticity Mechanisms:

  • RASGRF1 mediates calcium-dependent signaling in neurons

  • Phosphorylation at S916 potentially modulates its interaction with synaptic machinery

  • This may affect long-term potentiation and memory formation

• Neurodegenerative Disease Connections:

  • Alterations in RASGRF1 signaling are implicated in:

    • Age-related cognitive decline

    • Neurodegenerative processes

    • Response to ischemic injury

  • Phosphorylation status may serve as a biomarker for disease progression or treatment response

• Therapeutic Implications:

  • Potential therapeutic strategies:

    • miRNA-based approaches (miRNA-323-3p affects RASGRF1 expression)

    • Small molecule modulators of RASGRF1 phosphorylation

    • Gene therapy approaches to restore proper RASGRF1 function

  • Phospho-RASGRF1 antibodies could serve as tools for target engagement studies in drug development

How can integrative multi-omics approaches incorporate phospho-RASGRF1 (S916) data to provide a systems-level understanding of cellular signaling?

Modern systems biology approaches can contextualize RASGRF1 phosphorylation within broader cellular networks:

• Integration with Phosphoproteomics:

  • Mass spectrometry-based phosphoproteomics can identify:

    • Other phosphorylation sites on RASGRF1

    • Phosphorylation changes in pathway components

    • Novel interaction partners

  • Pathway enrichment analysis can place S916 phosphorylation in broader signaling contexts

• Multi-Omics Data Integration:

  • Correlate phosphorylation data with:

    • Transcriptomic changes (RNA-seq)

    • Proteomic alterations

    • Metabolomic shifts

  • Network analysis can reveal how RASGRF1 phosphorylation influences global cellular responses

• Temporal Analysis:

  • Time-resolved phosphorylation studies

  • Dynamic modeling of signaling cascades

  • Identification of feedback and feedforward mechanisms involving RASGRF1

• Computational Approaches:

  • Structural modeling of phosphorylation effects

  • Machine learning for prediction of phosphorylation consequences

  • Network perturbation analysis to identify critical nodes in RASGRF1-dependent pathways

• Single-Cell Technologies:

  • Single-cell phospho-profiling to capture cellular heterogeneity

  • Correlation with single-cell transcriptomics

  • Spatial methods to understand tissue-level organization of RASGRF1 signaling

What are the emerging applications of phospho-RASGRF1 (S916) antibodies in precision medicine approaches for cancer and other diseases?

Phospho-RASGRF1 (S916) antibodies have potential applications in precision medicine:

• Cancer Biomarker Development:

  • RasGRF1 activation correlates with proliferation and metastatic behavior in certain cancers

  • Phosphorylation at S916 could serve as:

    • Prognostic biomarker

    • Predictive biomarker for targeted therapies

    • Pharmacodynamic marker of treatment response

• Therapeutic Target Validation:

  • RasGRF1 knockdown reduces tumor growth in ARMS models

  • Phosphorylation status can indicate:

    • Target engagement by novel therapeutics

    • Compensatory pathway activation

    • Resistance mechanisms

• Patient Stratification:

  • Tumor phospho-profiling could identify:

    • Patients likely to respond to specific targeted therapies

    • Optimal combination therapy approaches

    • Resistance mechanisms for personalized treatment adjustment

• Theranostic Applications:

  • Development of companion diagnostics

  • Monitoring treatment response in real-time

  • Adapting treatment strategies based on phosphorylation changes

• Beyond Cancer:

  • Potential applications in:

    • Neurological disorders (based on cognitive function connections)

    • Inflammatory conditions

    • Metabolic diseases

  • Requires further validation in specific disease contexts